All Resources
Explore our latest resources
Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms
Exclusive agreement for AI algorithms to accelerate earlier detection of cardiac amyloidosis and pulmonary hypertension SAN FRANCISCO, CA – August...
Aug 25, 2023
Viz.ai Receives First De Novo Approval by the FDA for AI Algorithm for...
New artificial intelligence algorithm for earlier detection and management of hypertrophic cardiomyopathy SAN FRANCISCO, CA – August 15, 2023 -...
Aug 15, 2023
July 25, 2023
Takeaways from the 2023 Heart Rhythm Conference
The Viz team recently attended the 2023 Heart Rhythm Conference (HRS), which brought together leading Cardiac Electrophysiology experts (EPs) to...
Jun 13, 2023
Viz.ai Appoints Hypertrophic Cardiomyopathy Medical Advisory Board to Advance Innovation
Leading experts to shape the future of Viz.ai’s HCM strategy and platform SAN FRANCISCO - May 4, 2023 - Viz.ai,...
May 04, 2023
Key Takeaways from ACC 2023
The American College of Cardiology’s Annual Scientific Session & Expo together with the World Congress of Cardiology – ACC.23/WCC –...
Apr 13, 2023
Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management...
Viz.ai has submitted a de novo classification request to the FDA for a new AI algorithm intended to identify and...
Mar 02, 2023